BHR Partners is a Chinese private equity firm with a value-driven investment strategy focused on cross-border mergers and acquisitions, particularly facilitating the overseas expansion of Chinese enterprises and state-owned enterprise reforms. The firm primarily invests in high-tech industries, healthcare, advanced manufacturing, biotech, pharma, biomed, and traditional media, often targeting companies in the U.S. and Europe.
50% of their portfolio is in AI. Their most common stage is series-d (100% of deals).
Portfolio
2
Fund Size
$1.5B
Top Stage
Series D
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Portfolio
2 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| IInsilico | Series D | $95M | Aug 2022 |
 Insilico Medicine | Series D | $60M | Jun 2022 |
Top Co-Investors
Warburg Pincus2 shared
B Capital2 shared
Bold Capital Partners2 shared
Pavilion Capital2 shared
Prosperity7 Ventures1 shared
Last updated: 28 April 2026